Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Nelson Peltz’s New Big Secret Target

Page 1 of 2

Billionaire activist investor Nelson Peltz dropped some hints about Trian’s new big activist target at an investment conference in New York. Peltz said Trian has two new positions that account a third of its portfolio but he isn’t ready to disclose the names of these stocks. It wasn’t clear from his statements whether one of two stocks is Pentair (NYSE:PNR). According to the latest 13D filings, Trian had about 13 million shares of Pentair and probably spent close to $800 million to acquire them. Trian’s 13F portfolio was close to $9 billion at the end of March. Assuming that Pentair is one of Trian’s two new positions, Trian must have invested around $2 billion in the other “secret” stock.


We have been hearing about these two new positions for a while now and Trian hasn’t filed any 13Ds which they have to do within 10 days of acquiring a 5% activist stake in a company. This tells us that Trian spent $2 billion on the stock yet this wasn’t enough to give them a 5% stake in the company. This means Peltz’s new target is at least a $40 billion company. Trian’s preferred set of companies is very similar to the stocks Warren Buffett likes to invest. So, we doubt that his new target is a technology or energy stock. It is probably a consumer goods, industrial, or financial company.

We don’t know which stock they are now targeting but does it really matter? One of the hottest trends in investing over the last few years is ETFs and passive investing. A large number of investors lost confidence in active managers and they have been shifting their assets into index funds. It is a fact that most active money managers can’t beat the market after fees. Our in house research have shown that the 50 most popular large-cap stocks among hedge funds underperformed the market in our backtests though they were as risky as the market. After adjusting for risk they outperformed the market by less than a percentage point annually. Mutual fund managers’ track record is even worse. So, it is clear that an average fund manager and an average investor can’t really beat the market by a meaningful margin when they actively look for large-cap stocks. However, there are a few exceptions and smart investors benefited by taking advantage of these exceptions.

One is investing in small-cap stocks. Our research have shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by 0.95 percentage points per month in our back tests covering the 1999-2012 period. You will get double digit outperformance if you annualize this figure. We started tracking the performance of these 15 stocks in real time since the end of August 2012. These stocks outperformed the S&P 500 ETFs by 81 percentage points since then. The cumulative return of these stocks was 139.7% through July 14th vs. 58.7% gain for the S&P 500 ETFs (research results are here).

Nelson Peltz
Nelson Peltz
Trian Partners

The second exception is imitating the stock picks of certain fund managers. Warren Buffett is one of them. His large-cap picks handily beat the market over long-periods of time, including recent years (read the details here). Another one is Nelson Peltz. Our research indicates that Nelson Peltz’s mid and large-cap stock picks returned an average of 0.81% per month between 2008 and 2012. S&P 500 Index returned only 0.29% per month during the same period. This is an outperformance of more than 6 percentage points per year. Peltz’s stock picks were also less riskier than the market. His risk adjusted outperformance number is 54 basis points per month. Why is this important?

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!